戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 of ketamine, an NMDA receptor antagonist and psychotomimetic.
2 rough the previously investigated targets of psychotomimetics.
3 c dysfunction in animal and human studies, a psychotomimetic agent and a rapidly acting antidepressan
4  seen in humans and animals treated with the psychotomimetic agent ketamine.
5   Nonetheless, its use is limited due to its psychotomimetic and addictive properties.
6                                Ketamine is a psychotomimetic and antidepressant drug.
7 of these drugs, the main mechanism for their psychotomimetic and cognitive-impairing effects has been
8 ulation, may be necessary to account for the psychotomimetic and cognitive-impairing effects of this
9 7-78.49), respectively, accompanied by brief psychotomimetic and dissociative effects.
10          However, ketamine induces undesired psychotomimetic and dissociative side effects that limit
11 s to produce antidepressant efficacy without psychotomimetic and dissociative side effects.
12 ly gained significant attention owing to its psychotomimetic and more recently discovered rapid antid
13 al mechanism by which CBD may counteract the psychotomimetic and psychotropic side effects of THC.SIG
14 ns, regulating the response to neuroleptics, psychotomimetics, and drugs of abuse, and affecting stri
15 phic gamma band power, possibly reflecting a psychotomimetic aspect of ketamine's effect, and is cont
16 ses were measured to investigate THC-induced psychotomimetic behavior.
17 y measured in the ventral tegmental area and psychotomimetic behavioral analyses.
18                        Intriguingly, another psychotomimetic compound, ketamine, is a fast-acting ant
19                                    Potential psychotomimetic, dissociative, hemodynamic, and general
20                                 A single sub-psychotomimetic dose of ketamine, an ionotropic glutamat
21 uits may account for the association between psychotomimetic drug abuse and poor outcomes in schizoph
22 s prompted investigations into the nature of psychotomimetic drug effects on PFC neuronal activity.
23 ithin PV+ cells, reversibly inhibited by the psychotomimetic drug ketamine, play a critical role in S
24                           The effects of the psychotomimetic drug phencyclidine on the neurochemistry
25 studies demonstrated differential effects of psychotomimetic drugs (cocaine and methamphetamine) on n
26 onists also modulate the in vivo activity of psychotomimetic drugs and reduce the ability of psychoto
27 attempts to reliably induce a PPI deficit by psychotomimetic drugs have not been successful, leaving
28 s including prepulse inhibition, response to psychotomimetic drugs, and social interaction.
29 tamine but qualitatively distinct from other psychotomimetic drugs, including ketamine, amphetamine,
30                        Furthermore, abuse of psychotomimetic drugs, which exacerbate reality distorti
31                                          The psychotomimetic effect of the N-methyl-D-aspartate recep
32                                              Psychotomimetic effects (Positive and Negative Syndrome
33 impairing (delayed-matching-to-position), or psychotomimetic effects (specifically, phencyclidine dis
34  a rapid-acting antidepressant devoid of the psychotomimetic effects and abuse potential of ketamine.
35 a marker of greater sensitivity to its acute psychotomimetic effects and may have important public he
36                                  SA produced psychotomimetic effects and perceptual alterations, incl
37 tabolites as mediators of antidepressant and psychotomimetic effects and their relationship to restin
38 c acid/glutamate receptor antagonists induce psychotomimetic effects in humans and animals, and much
39 orking memory on a CogState battery; and (3) psychotomimetic effects measured by the Positive and Neg
40       This is consistent with the absence of psychotomimetic effects observed for this class of drugs
41 provide a plausible mechanism underlying the psychotomimetic effects of cannabinoids.
42 reases in neural noise may contribute to the psychotomimetic effects of Delta(9)-THC.
43 t neural noise could also be involved in the psychotomimetic effects of delta-9-tetrahydrocannabinol
44 to individuals who were not sensitive to the psychotomimetic effects of Delta9-THC, individuals who d
45 en implicated in psychiatric illness and the psychotomimetic effects of hallucinogens.
46  resonance spectroscopy, underlies the acute psychotomimetic effects of intravenously administered de
47      This overview includes evidence for the psychotomimetic effects of kappa opioid receptor agonist
48  exhibits antidepressant effects without the psychotomimetic effects of ketamine, has fueled interest
49  of various lines of evidence, including the psychotomimetic effects of NMDA receptor antagonists.
50          Specifically, we review data on the psychotomimetic effects of sleep deprivation in healthy
51           However, ketamine can also produce psychotomimetic effects that limit its utility as an ant
52 BA deficit would create vulnerability to the psychotomimetic effects to the 'subthreshold' dose of AM
53 d but short-lived antidepressant effects; no psychotomimetic effects were observed.
54  NMDA receptor (NMDA-R) antagonist, produces psychotomimetic effects when administered in sub-anesthe
55  function, abuse liability, psychedelic, and psychotomimetic effects, mood, and anxiety were assessed
56 se events and no evidence of dissociative or psychotomimetic effects, opioid effects, or withdrawal s
57          Concomitantly, Delta(9)-THC induced psychotomimetic effects, perceptual alterations, and sub
58 methorphan-bupropion was not associated with psychotomimetic effects, weight gain, or sexual dysfunct
59 eart rate, anxiety, psychedelic effects, and psychotomimetic effects, which resolved within 20-30 min
60 amine produced dose-related dissociative and psychotomimetic effects, which returned to baseline with
61 t significantly attenuating ketamine-induced psychotomimetic effects.
62 to the magnitude and spectrum of their acute psychotomimetic effects.
63 e frequency and severity of dissociative and psychotomimetic effects.
64 channel blocker with low rates of associated psychotomimetic effects.
65 d by its abuse potential as well as possible psychotomimetic effects.
66 chotomimetic drugs and reduce the ability of psychotomimetic hallucinogens to increase glutamatergic
67  alterations both in sensorimotor gating and psychotomimetic-induced locomotor activity.
68                        Systemic doses of the psychotomimetic ketamine alter the spectral characterist
69 Glu5 NAM MTEP across models of addiction and psychotomimetic-like activity.
70 e effects, including psychosis in humans and psychotomimetic-like effects in animals, suggesting a na
71 erbation was induced with an infusion of the psychotomimetic methylphenidate hydrochloride (0.5 mg/kg
72 effect of R,S-ketamine in the absence of any psychotomimetic or abuse-related effects.
73 s observed between the groups with regard to psychotomimetic or dissociative adverse effects.
74 sal ketamine was well tolerated with minimal psychotomimetic or dissociative effects and was not asso
75 ficantly reduced depressive symptoms without psychotomimetic or dissociative effects.
76  to represent spatial knowledge, we used the psychotomimetic phencyclidine (PCP) to disrupt cognitive
77                                  We used the psychotomimetic phencyclidine (PCP) to investigate the r
78  of the NMDA/glutamate receptor, such as the psychotomimetic phencyclidine (PCP).
79                                          The psychotomimetic phencyclidine and its potent congener di
80  receptor antagonist phencyclidine (PCP) has psychotomimetic properties in humans and activates the f
81 ntal cortex (PFC) neurons in reinforcing and psychotomimetic properties of psychostimulants, yet litt
82  exerts rapid antidepressant effects but has psychotomimetic properties.
83 consumption in mice, including sex-dependent psychotomimetic responses.
84                    Because Salvinorin A is a psychotomimetic selective for kappa opioid receptors, ka
85 oral responses may be related to the lack of psychotomimetic side effects of GLYX-13 compared with ke
86 ceptor complex, but without dissociative and psychotomimetic side effects of ketamine.
87 apid antidepressant effects, but without the psychotomimetic side effects of ketamine.
88 d limited clinical value due to debilitating psychotomimetic side-effects.
89  line of thinking is that these drugs create psychotomimetic states by similarly disinhibiting the ac
90 atergic antagonists (such as PCP) all induce psychotomimetic states in experimental animals that clos
91 I and self-reported psychosis-like symptoms (Psychotomimetic States Inventory) were measured in 24 he
92  subanesthetic dose of ketamine causes acute psychotomimetic symptoms and sustained antidepressant ef
93 ine metabolites and response, diagnosis, and psychotomimetic symptoms in MDD and BD patients.
94 een ketamine metabolites, clinical response, psychotomimetic symptoms, and gamma power changes in 34
95 the 4-item Positive Symptom Rating Scale for psychotomimetic symptoms, the Clinician-Administered Dis
96 e positively associated with contemporaneous psychotomimetic symptoms; post-hoc analysis revealed tha